Corporate Synergies in Alzheimer Disease

  • NanoNewron is focused on the delivery of biologicals to the brain with a lead therapeutic product (NN-841) targeting TNFα in AD patients.
  • Development of NN-841 is being supported by grants from NIH
  • NanoNewron is open to the collaboration for NN-841 with corporate partners with global product development and market reach in AD

Licensing Opportunities for NewroBus Technology

  • Availability for licensing for use in combination with marketed products for Life Cycle management
  • Improving delivery of a pipeline product into the CNS with NewroBus technology for better efficacy and/or safety in neurological diseases

To access our latest non-confidential corporate presentation, click here.
To review our FCOI Policies, click here.

Scroll to Top